{"version":"1.0","provider_name":"Cancer Research Institute","provider_url":"https:\/\/www.cancerresearch.org\/es","title":"Paolo Bossi, MD - Cancer Research Institute","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"Ux8Vnu66O2\"><a href=\"https:\/\/www.cancerresearch.org\/es\/cri-funded-scientists\/paolo-bossi-md\">Paolo Bossi, MD<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.cancerresearch.org\/es\/cri-funded-scientists\/paolo-bossi-md\/embed#?secret=Ux8Vnu66O2\" width=\"600\" height=\"338\" title=\"\u00abPaolo Bossi, MD\u00bb \u2014 Cancer Research Institute\" data-secret=\"Ux8Vnu66O2\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.cancerresearch.org\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","thumbnail_url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/08\/Bossi-Paolo-e1754514702639.jpg","thumbnail_width":732,"thumbnail_height":529,"description":"The APHRODITE Trial focuses on mitazalimab, an immune-stimulating, \u201corphan\u201d drug that activates a pathway called CD40, which plays a key role in immune surveillance and tumor prevention. In this phase II trial, patients with high-risk OPMDs will receive mitazalimab over an eight-week period. After six months, the team will assess whether the treatment reduced or eliminated abnormal tissue and evaluate its safety, impact on cancer risk, and effects on quality of life."}